首页> 美国卫生研究院文献>British Journal of Cancer >Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

【2h】

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

机译：Cediranib联合mFOLFOX6与贝伐单抗联合mFOLFOX6在先前治疗的转移性大肠癌中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors. Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC).

机译：背景：西地尼布是一种高效的血管内皮生长因子（VEGF）信号抑制剂，对所有三种VEGF受体均具有活性。贝伐单抗是一种抗VEGF-A单克隆抗体，在先前治疗的转移性结直肠癌（mCRC）中具有临床益处。

著录项

期刊名称 British Journal of Cancer
作者
D Cunningham; R P W Wong; G DHaens; J-Y Douillard; J Robertson; A M Stone; E Van Cutsem;
展开▼
作者单位

展开▼
年(卷),期 2013(108),3
年度 2013
页码 493–502
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
cediranib mFOLFOX6 bevacizumab metastatic colorectal cancer;

机译：西地那尼;mFOLFOX6;贝伐单抗;转移性;结直肠癌;

相似文献

外文文献
中文文献
专利

1. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer [J] . D Cunningham, R P W Wong, G DHaens, British Journal of Cancer . 2013,第3期

机译：Cediranib与mFOLFOX6对比贝伐单抗与mFOLFOX6在先前治疗的转移性大肠癌中
2. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III) [J] . SchmollH.-J., CunninghamD., SobreroA., Journal of Clinical Oncology . 2012,第29期

机译：西地尼单抗联合mFOLFOX6与贝伐单抗联合mFOLFOX6作为晚期大肠癌患者的一线治疗：一项双盲，随机III期研究（HORIZON III）
3. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer [J] . T. Walter Colon & Rectum . 2016,第3期

机译：SIRFLOX：转移性结直肠癌患者一线mFOLFOX6（加或减贝伐单抗）与mFOLFOX6（加或减贝伐单抗）加选择性内部放射治疗的三期随机对照试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Guanylyl Cyclase C Vaccines for Secondary Prevention of Metastatic Colorectal Cancer [D] . Flickinger, John C., Jr. 2023

机译：古达利环酶C疫苗用于转移性结直肠癌的二级预防
6. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label non-inferiority randomised phase III: SOFT study [O] . Hideo Baba, Yasuhide Yamada, Daisuke Takahari, 2017

机译：S-1和奥沙利铂（SOX）加贝伐单抗与mFOLFOX6加贝伐单抗作为转移性结直肠癌患者的一线治疗：开放标签非自卑性随机III期的最新总体生存分析：SOFT研究
7. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer [O] . Cunningham, D, Wong, R P W, D'Haens, Geert, 2013

机译：Cediranib联合mFOLFOX6与贝伐单抗联合mFOLFOX6在先前治疗的转移性大肠癌中

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅